Dexrazoxane Not Associated with Late Mortality in Pediatric Patients

Share this content:

the Cancer Therapy Advisor take:

After extended follow-up, dexrazoxane treatment did not seem to compromise overall survival among pediatric patients with leukemia or lymphoma, according to a report from the Children’s Oncology Group and published online this week in the Journal of Clinical Oncology.

The three clinical trials conducted over a 5-year period were P9404 (T-cell acute lymphoblastic leukemia/lymphoma; n = 537), P9425 (intermediate/high-risk Hodgkin lymphoma; n = 216), and P9426 (low-risk Hodgkin lymphoma; n = 255).

The patients in each trial were randomly assigned to receive dexrazoxane and doxorubicin or doxorubicin alone. The dose ratio for dexrazoxane to doxorubicin was 10:1 where dexrazoxane was given as IV bolus prior to doxorubicin.

Out of 507 patients (1,008 total patients) treated with dexrazoxane, 67 died (132 total deaths) during a median follow-up of 12.6 years.

In general, there was no significant mortality difference based on dexrazoxane status where the mortality with and without dexrazoxane were12.8% and 12.2%, respectively (HR=1.03; 95% CI, 0.73-1.45).

Morality was mostly associated with the original cancer with 76.5% (HR=0.90; 95% CI, 0.61-1.32) of all deaths caused by the original cancer and 13.6% (HR=1.24; 95% CI, 0.49-3.15) of all deaths caused by second cancers.

The researchers found that dexrazoxane was not associated with deaths caused by acute myeloid leukemia/myelodysplasia or cardiovascular events.

Pediatric patients treated with ifosfamide-doxorubicin chemotherapy and radiotherapy experienced sat
Dexrazoxane treatment did not seem to compromise overall survival among pediatric patients with leukemia or lymphoma.
Given concerns that dexrazoxane may reduce treatment efficacy, induce second cancers, and thus compromise overall survival among children, we examined long-term overall and cause-specific mortality and disease relapse rates from three randomized clinical trials.
READ FULL ARTICLE From Ascopubs

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters